Published in Nat Med on September 01, 1996
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res (2011) 3.18
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest (1997) 2.32
New molecularly targeted therapies for lung cancer. J Clin Invest (2007) 1.86
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
p53-based cancer therapy. Cold Spring Harb Perspect Biol (2010) 1.62
Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J (1998) 1.62
Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J (1997) 1.60
TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 1.46
Recent advances in p53 research and cancer treatment. J Biomed Biotechnol (2011) 1.31
Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol (2012) 1.04
Smoking, p53 mutation, and lung cancer. Mol Cancer Res (2014) 1.03
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res (2008) 1.01
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One (2012) 1.00
Chemokines: can effector cells be redirected to the site of the tumor? Cancer J (2010) 0.98
The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir Res (2003) 0.97
Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions. Protein Sci (1999) 0.95
Targeted molecular imaging. Korean J Radiol (2004) 0.91
Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) (2013) 0.89
Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut (2004) 0.89
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med (2015) 0.88
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (1999) 0.88
Translational research comes of age. Nat Med (1996) 0.88
Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo. Sci Rep (2015) 0.88
In vitro evolution of thermostable p53 variants. Protein Sci (1999) 0.88
Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. Genet Vaccines Ther (2008) 0.86
Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology (2014) 0.86
Oxidative Stress Induced by MnSOD-p53 Interaction: Pro- or Anti-Tumorigenic? J Signal Transduct (2011) 0.86
Immunotherapy in lung cancer. Br J Cancer (1998) 0.86
Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics (2014) 0.86
Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex. World J Gastroenterol (2003) 0.85
Gene therapy for lung neoplasms. Clin Chest Med (2011) 0.84
Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up. J Zhejiang Univ Sci B (2009) 0.83
Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res (2014) 0.83
Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol (2015) 0.83
p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br J Cancer (2000) 0.82
Gene- and viral-based therapies for brain tumors. Neurotherapeutics (2009) 0.81
Expression of TIP-1 confers radioresistance of malignant glioma cells. PLoS One (2012) 0.81
Functional repair of p53 mutation in colorectal cancer cells using trans-splicing. Oncotarget (2015) 0.80
Apoptosis after gamma irradiation. Is it an important cell death modality? Br J Cancer (1998) 0.80
Cancer gene therapy clinical trials: lessons for the future. Br J Cancer (2001) 0.80
Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA. Nanomedicine (Lond) (2012) 0.80
Glycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells. Mol Cancer (2002) 0.79
Co-transduction of Apaf-1 and caspase-9 highly enhances p53-mediated apoptosis in gliomas. Br J Cancer (2002) 0.79
p53 status of newly established acute myeloid leukaemia cell lines. Br J Cancer (1999) 0.78
Serum p53 antibodies: predictors of survival in small-cell lung cancer? Br J Cancer (2000) 0.78
Gene therapy--its potential in surgery. Ann R Coll Surg Engl (2002) 0.77
New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder. World J Urol (1997) 0.77
Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines. J Gynecol Oncol (2009) 0.77
Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells. Oncotarget (2014) 0.76
Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies. Breast Cancer Res (1999) 0.76
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Transl Cancer Res (2016) 0.76
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol (2016) 0.75
Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model. J Biomed Sci (2016) 0.75
Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol (2011) 0.75
Demystified ... p53. Mol Pathol (1998) 0.75
The promise and reality of cancer gene therapy. Am J Hum Genet (1997) 0.75
Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy. Mol Ther Oncolytics (2017) 0.75
Cancer-risk module identification and module-based disease risk evaluation: a case study on lung cancer. PLoS One (2014) 0.75
The minimal gene complement of Mycoplasma genitalium. Science (1995) 32.41
Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature (1981) 16.61
Calcium oscillations increase the efficiency and specificity of gene expression. Nature (1998) 9.19
Head and neck cancer. N Engl J Med (1993) 6.33
The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell (1997) 6.10
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst (1994) 4.21
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell (1990) 3.70
Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst (1998) 3.17
Retracted Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet (2005) 3.13
Microevolution of the direct repeat region of Mycobacterium tuberculosis: implications for interpretation of spoligotyping data. J Clin Microbiol (2002) 3.12
Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst (1997) 3.03
Invasion of brain microvascular endothelial cells by group B streptococci. Infect Immun (1997) 2.97
Molecular cloning and sequencing of the Mexico isolate of hepatitis E virus (HEV). Virology (1992) 2.92
N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol (2001) 2.91
Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg (2000) 2.88
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst (1995) 2.64
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res (1995) 2.56
Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem (2000) 2.51
Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys (1995) 2.50
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst (2000) 2.39
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Surgical treatment of cardiac tumors: a 25-year experience. Ann Thorac Surg (1990) 2.34
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst (2000) 2.33
Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies. J Immunol (1997) 2.30
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg (1995) 2.25
The product of hedgehog autoproteolytic cleavage active in local and long-range signalling. Nature (1995) 2.24
Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med (2000) 2.19
Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst (2001) 2.18
Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst (1998) 2.16
Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst (1994) 2.15
Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst (2001) 2.13
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys (2001) 2.10
Tracheobronchial tree: expandable metallic stents used in experimental and clinical applications. Work in progress. Radiology (1986) 2.05
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest (1999) 2.05
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
Individual classification of mild cognitive impairment subtypes by support vector machine analysis of white matter DTI. AJNR Am J Neuroradiol (2012) 2.04
Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Cell (1996) 2.04
Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med (1992) 2.03
Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst (1997) 2.01
Reduction of systemic drug exposure after hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration. Surgery (1993) 2.01
Survival in early-stage non-small cell lung cancer. Ann Thorac Surg (1995) 2.01
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell (1998) 2.00
Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.98
Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer (1998) 1.97
Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys (1991) 1.97
Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res (1997) 1.96
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res (1999) 1.95
Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol (2003) 1.94
Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol (2000) 1.93
A marker-assisted backcross approach for developing submergence-tolerant rice cultivars. Theor Appl Genet (2007) 1.93
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol (2000) 1.93
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol (1998) 1.92
The fidelity of human DNA polymerase gamma with and without exonucleolytic proofreading and the p55 accessory subunit. J Biol Chem (2001) 1.92
Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res (2001) 1.91
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology (2000) 1.90
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci (2001) 1.90
Interaction between a functional MAOA locus and childhood sexual abuse predicts alcoholism and antisocial personality disorder in adult women. Mol Psychiatry (2007) 1.88
CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J Immunol (1994) 1.87
Cancer chemoprevention: progress and promise. J Natl Cancer Inst (1998) 1.87
Ligand cross-reactivity within the protease-activated receptor family. J Biol Chem (1996) 1.86
Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst (1994) 1.83
Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg (2000) 1.83
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.81
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res (2000) 1.81